|
KMID : 1141720210090010011
|
|
폐쇄성폐질환
2021 Volume.9 No. 1 p.11 ~ p.15
|
|
|
|
|
Lee Ye-Jin
Park Yong-Bum
|
|
|
Abstract
|
|
|
|
A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), was first identified in December 2019 Wuhan, China. Today, COVID 19 has officially become a pandemic and the number of newly confirmed COVID 19 patients has exceeded 1,000 every day, the highest ever in Korea. Many randomized control trials have been evaluated for the treatment of COVID 19, only dexamethasone and remdesivir have proven effective in severe COVID 19 patients who require oxygen supplementation, whereas, hydroxychloroquine was failed to show efficacy. In addition, several antibodies from convalescent plasma for COVID 19 is still under clinical trial and is not approved. Currently, considerable efforts have been put into developing effective and safe vaccines against SARS-COV-2. Global pharmaceutics e.g, Astrazeneca, Moderna, and Pfizer are developing RNA or non-replicating vector vaccines and we hope that these vaccines provide acquired immunity against COVID-19 with safety.
|
|
|
KEYWORD
|
|
|
SARS-COV-2, COVID-19, Hydroxychloroquine, Dexamethasone, Remdesivir, Antibodies, Vaccine against COVID-19
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|